C1 of binding to the α_4 subunit of VLA-4, in an amount effective to treat diabetes.

~~9~~ 12. (Amended) A method according to claim [11] ~~10~~ 1, C2 wherein the soluble VCAM-1 polypeptide[s] comprise a VCAM-IgG fusion.

~~13~~ 13. (Amended) A method according to claim [11] ~~10~~ 1, wherein the composition is administered in an amount effective to provide a plasma level of a soluble VCAM-1 polypeptide[s] in the mammal of at least 10-20 μg/ml over a period of 1-14 days.

~~16~~ 14. (Thrice Amended) A method according to claim ~~10~~ 1, C3 wherein the composition is administered at a dosage so as to provide from about 0.1 to about 10 mg/kg of antibody or [antibody fragment] an antigen binding fragment of said antibody, based on the weight of the susceptible mammal.

~~17~~ 15. (Amended) A method according to claim ~~10~~ 1, wherein C4 the composition is administered in an amount effective to [coat] block VLA-4 antigen on VLA-4 positive cells in the peripheral blood for a period of 1-14 days.

~~25~~ 9 16. (Twice Amended) A method according to claim ~~10~~ 1, C5 wherein the composition comprises an antibody or an antigen binding fragment of [such] said antibody capable of binding to the α_4 subunit of VLA-4.

51